Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13230MR)

This product GTTS-WQ13230MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13230MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9536MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ2307MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ9036MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ15845MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ15835MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ11033MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ7199MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ4136MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW